Cubist jumps on to Heptares' growing GPCR bandwagon

The drug discovery team at Heptares Therapeutics landed in San Francisco today with news of yet another development pact with a well-known biopharma player. This time it's Boston, MA-based Cubist Pharmaceuticals ($CBST), which has jumped on the Heptares platform to find new drugs targeting G protein-coupled receptors (GPCRs). Heptares is pocketing a $5 million upfront payment and $4 million in...